Citi analyst Liav Abraham sees a greater than 50% chance of a Teva (TEVA), Mylan (MYL) deal consummating should Mylan shareholders vote against the proposed buyout of Perrigo (PRGO). Abraham continues to believe the likelihood of a Teva, Mylan transaction is being underappreciated by investors. His estimates "clearly" favor the economics of a Teva, Mylan combination versus a Mylan, Perrigo combination.

Vanda Pharmaceuticals "announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ(R) Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp." CEO Mihael H. Polymeropoulos stated: "We are disappointed that the Supreme Court has decided not to hear our case and clarify the lower court standard for obviousness in patent law. However, we are pleased that our case has drawn attention to an area of law that has broad and significant implications in life sciences innovation."